IFNA2 and neoplasm: BRAF V600E mutant (A375) and BRAF wild-type (WM1366 and MeWo) human melanoma tumor cells were plated at a density of 3 × 104 cells/well in 96 well plates and treated with complete medium supplemented with either 10% DMSO, 35 nM ixazomib, 103 U/mL IFN-α, or the combination of ixazomib plus IFN-α for 48 hours.